Hemant Surgical Industries
Hemant Surgical Industries
HealthcareKey Fundamentals
SMEMedical EquipmentHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has delivered good profit growth of 68.0% CAGR over last 5 years
- Company's working capital requirements have reduced from 45.5 days to 24.0 days
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -6.07%
- Debtor days have increased from 83.7 to 106 days.
Growth Rate
Quarterly Results
| Particulars | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 | 64 | 167 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 | 57 | 151 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 | 8 | 16 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% | 12% | 9% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 | 2 | 3 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 4 | 6 | 5 | 8 | 4 | 6 | 7 | 16 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% | 25% | 22% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 | 5 | 13 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 | 4.15 | 9.84 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 231 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 208 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 23 |
| OPM % | 4.9% | 4.8% | 4.7% | 5% | 6% | 10% | 10% | 9% | 10% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 6 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 4 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 2 |
| PBT | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 24 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | 23% |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 18 |
| EPS in Rs | 50.76 | 61.02 | 27 | 73.43 | 249 | 9.95 | 9.39 | 7.79 | 13.98 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 | 13 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 | 124 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 | 50 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 | 87 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 | 53 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 0 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 | 0 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 | 220 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 274 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 0 | 2 | -4 | 12 | 6 | -4 | 9 | -32 |
| Investing | 0 | 0 | -2 | -2 | 0 | -3 | -12 | -30 | -3 |
| Financing | 0 | 0 | 2 | 5 | -8 | -1 | 21 | 18 | 69 |
| Net Cash Flow | 0 | 0 | 2 | -2 | 4 | 3 | 5 | -4 | 34 |
| Free Cash Flow | 0 | 0 | -1 | -7 | 12 | 2 | -13 | -25 | -34 |
| CFO/OP | 0 | 0 | 68 | -127 | 197 | 84 | -9 | 126 | -118 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 | 106 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 205 | 120 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 | 146 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 | 80 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 | 24 |
| ROCE % | — | 15% | 12% | 14% | 32% | 45% | 30% | 16% | 20% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Hemant Surgical Industries insights
53 extracted metrics + investor summaries across FY18–FY26.
Documents
Frequently Asked Questions about Hemant Surgical Industries
What does Hemant Surgical Industries Ltd do?
Where is Hemant Surgical Industries Ltd (543916) listed?
Which sector does Hemant Surgical Industries Ltd belong to?
What is the market capitalisation of Hemant Surgical Industries Ltd?
What is the PE ratio of Hemant Surgical Industries Ltd?
What is the 52-week high and low of Hemant Surgical Industries Ltd?
What is the Return on Equity (ROE) of Hemant Surgical Industries Ltd?
Company Information
Incorporated in 1989, Hemant Surgical Industries Ltd is in the business of Medical Equipment & Supplies[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543916.md for Hemant Surgical Industries Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.